Humalog Shortage: What Providers and Prescribers Need to Know in 2026

The 2024 Humalog shortage placed significant strain on diabetes care practices nationwide. Patients with Type 1 diabetes — many of whom cannot tolerate any gap in rapid-acting insulin access — faced disruptions that required urgent clinical intervention. While the acute shortage has largely resolved as of 2026, providers need to be prepared for the possibility of future localized stockouts and have clear protocols in place.

This guide covers the current status of Humalog availability, clinical guidance for switching patients to alternatives, formulary navigation strategies, patient assistance programs, and how medfinder can support your practice.

Current Shortage Status (2026)

As of 2026, Humalog (insulin lispro) is not listed as an active shortage on the FDA Drug Shortages database or the ASHP Drug Shortage Resource Center. The national supply of Humalog 10 mL U-100 vials and all KwikPen formats has largely stabilized following the 2024 manufacturing disruptions.

Key changes from the 2024 shortage that remain permanent:

• 3 mL vials permanently discontinued. Prescriptions written for 3 mL Humalog or insulin lispro vials should be updated to 10 mL vials or KwikPen formats to avoid fill failures.
• Localized stockouts persist. Some community and independent pharmacies may still experience intermittent stock gaps. Encourage patients to check multiple pharmacies.

Therapeutic Alternatives: Clinical Comparison

When Humalog is unavailable, the following rapid-acting insulins are clinically appropriate alternatives. All are FDA-approved for Type 1 and Type 2 diabetes.

Admelog (Insulin Lispro, Sanofi)

Admelog contains the same active ingredient (insulin lispro) as Humalog. Pharmacokinetic profile is identical: onset approximately 15 minutes, peak at 1 hour, duration 2–4 hours. Dose conversion is 1:1. Admelog is available as 10 mL vials and SoloStar prefilled pens. It does not have interchangeable biosimilar status, so a new prescription specifically for Admelog is required.

NovoLog / Fiasp (Insulin Aspart, Novo Nordisk)

Insulin aspart (NovoLog) is the second major rapid-acting insulin analog. Onset is 10–20 minutes, peak at 1–3 hours, duration 3–5 hours. Dose conversion from Humalog is typically 1:1, though individual titration may be needed. NovoLog is appropriate for use in insulin pumps (CSII). Note that Novo Nordisk discontinued NovoLog 10 mL vials, 3 mL FlexPens, and PenFill cartridges as of December 31, 2025. Only the FlexTouch pen remains. Fiasp offers a faster onset and is suitable for patients who benefit from post-meal flexibility.

Apidra (Insulin Glulisine, Sanofi)

Insulin glulisine has a similar pharmacokinetic profile to insulin lispro. It is less commonly prescribed, which may confer a practical advantage during shortage periods. Approved for patients ≥4 years old. Dose conversion from Humalog is 1:1. Available as vials and SoloStar prefilled pens.

Lyumjev (Insulin Lispro-aabc, Eli Lilly)

Lyumjev is an ultra-rapid formulation of insulin lispro. It contains the same core insulin molecule as Humalog with added excipients (treprostinil and citrate) that accelerate absorption. Approved for adults ≥18 only. Because it shares the lispro molecule, the transition from Humalog to Lyumjev is generally smooth, but dose timing may need to be adjusted (given at meal start or up to 20 minutes after eating).

Switching Protocol Recommendations

When transitioning patients from Humalog to an alternative rapid-acting insulin:

1. Start with a 1:1 unit-for-unit dose conversion for Admelog, NovoLog, and Apidra.
2. Counsel patients to monitor blood glucose more frequently for the first 3–5 days after the switch.
3. For patients on CSII (insulin pumps), verify compatibility of the alternative insulin with the patient's pump and infusion set.
4. Adjust insulin-to-carbohydrate ratios and correction factors as needed based on SMBG or CGM data.
5. For Fiasp or Lyumjev, note the faster onset requires adjustment of meal timing — dose at meal start, not 15 minutes before.

Formulary and Insurance Considerations

Most commercial plans and PBMs include at least one rapid-acting insulin analog on their formulary. When switching a patient:

• Verify the alternative is covered on the patient's specific plan before writing the new prescription. Admelog may be preferred tier on some plans.
• Some plans require prior authorization for non-preferred rapid-acting insulins. Prepare documentation explaining the clinical necessity.
• The Lilly Insulin Value Program covers Humalog and Lyumjev at $35/month; Sanofi's Insulins Valyou Savings Program covers Admelog and Apidra at $35/month; NovoCare Savings covers NovoLog/Fiasp at $25/prescription.

Patient Assistance Programs

For uninsured or underinsured patients:

• Lilly Cares Foundation: Free insulin for patients at or below 400% of the federal poverty level. Call 1-800-545-6962 or visit LillyCares.com.
• Lilly Insulin Value Program: $35/month cap with or without insurance. Download savings card at insulinaffordability.com.
• Medicare Part D: $35/month insulin cap under the Inflation Reduction Act for all covered insulins.

How medfinder Supports Your Patients

When Humalog is unavailable at a patient's usual pharmacy, the process of locating stock can take hours of phone calls — time most patients don't have, and time your staff shouldn't spend. medfinder calls pharmacies on your patient's behalf to find which ones have Humalog — or a specific alternative — in stock and ready to fill. Consider sharing medfinder.com with patients who are experiencing fill difficulties. See also our guide on how to help your patients find Humalog in stock.